Microdosing psychedelics: More questions than answers? An overview and suggestions for future research:
Kim P. C. Kuypers,Livia Ng,David Erritzoe,Gitte M. Knudsen,Charles D. Nichols,David E. Nichols,Luca Pani,Anais Soula,David J. Nutt +8 more
TLDR
It is concluded that while most anecdotal reports focus on the positive experiences with microdosing, future research should also focus on potential risks of (multiple) administrations of a psychedelic in low doses, and (pre)clinical studies including biological as well as cognitive parameters have to be conducted to shed light on the potential negative consequencesmicrodosing could have.Abstract:
Background:In the past few years, the issue of ‘microdosing’ psychedelics has been openly discussed in the public arena where claims have been made about their positive effect on mood state and cog...read more
Citations
More filters
Journal ArticleDOI
Psychedelic Psychiatry's Brave New World.
TL;DR: Outcomes of neuroscience and clinical research into 5-Hydroxytryptamine 2A (5-HT2A) receptor agonists, such as psilocybin, show promise for addressing a range of serious disorders, including depression and addiction.
Journal ArticleDOI
The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects
TL;DR: Data is presented suggesting that the subjective effects induced by psychedelics may not be necessary to produce long-lasting changes in mood and behavior.
Journal ArticleDOI
Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies
TL;DR: Although the main focus was on efficacy and safety, study characteristics, duration of antidepressants effects across studies, and the role of the subjective drug experiences were also reviewed and presented.
Journal ArticleDOI
Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects.
Friederike Holze,Friederike Holze,Patrick Vizeli,Patrick Vizeli,Laura Ley,Laura Ley,Felix Müller,Patrick C. Dolder,Patrick C. Dolder,Melanie Stocker,Melanie Stocker,Urs Duthaler,Urs Duthaler,Nimmy Varghese,Anne Eckert,Stefan Borgwardt,Matthias E. Liechti,Matthias E. Liechti +17 more
TL;DR: The LSD dose–response curve showed a ceiling effect for subjective good effects, and ego dissolution and anxiety increased further at a dose above 100 µg, which may assist with dose finding for future LSD research.
Journal ArticleDOI
Chronic, Intermittent Microdoses of the Psychedelic N,N-Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents
Lindsay P. Cameron,Charlie J Benson,Brian C. DeFelice,Oliver Fiehn,Oliver Fiehn,David E. Olson +5 more
TL;DR: It is found that chronic, intermittent, low doses of DMT produced an antidepressant-like phenotype and enhanced fear extinction learning without impacting working memory or social interaction.
References
More filters
Journal ArticleDOI
A review of central 5-HT receptors and their function
Nicholas M. Barnes,Trevor Sharp +1 more
TL;DR: A number of 5-HT receptor ligands are currently utilised, or are in clinical development, to reduce the symptoms of CNS dysfunction and the functional responses attributed to each receptor in the brain are reviewed.
Journal ArticleDOI
Valvular Heart Disease Associated with Fenfluramine–Phentermine
Heidi M. Connolly,Jack L. Crary,Michael D. McGoon,Donald D. Hensrud,Brooks S. Edwards,William D. Edwards,Hartzell V. Schaff +6 more
TL;DR: Concerns are raised that fenfluramine-phentermine therapy may be associated with valvular heart disease, which is arouse concern about serious potential adverse effects, including pulmonary hypertension and valvULAR heart disease.
Book
Kaplan & Sadock's Comprehensive Textbook of Psychiatry
TL;DR: Kaplan & Sadock's comprehensive textbook of psychiatry as discussed by the authors, which is a comprehensive text of psychiatry, has been published by the University of Edinburgh since 2003. http://www.kahnandSadock.edu.
Journal ArticleDOI
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
Roland R. Griffiths,Matthew W. Johnson,Michael A. Carducci,Annie Umbricht,William A. Richards,Brian D Richards,Mary P Cosimano,Margaret A. Klinedinst +7 more
TL;DR: High-dose psilocybin produced large decreases in clinician- and self-rated measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety.
Journal ArticleDOI
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Robin L. Carhart-Harris,Mark Bolstridge,James Rucker,Camilla M. Day,David Erritzoe,Mendel Kaelen,Michael A P Bloomfield,James Rickard,Ben Forbes,Amanda Feilding,David Taylor,Steve Pilling,Valerie Curran,David J. Nutt +13 more
TL;DR: Preliminary support for the safety and efficacy of psilocybin for treatment-resistant depression is provided and motivates further trials, with more rigorous designs, to better examine the therapeutic potential of this approach.